

**Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells**


Anna Parente-Ribes,<sup>1\*</sup> Sigrid S. Skånland,<sup>2,3\*</sup> Simone Bürgler,<sup>1,4\*</sup> Audun Os,<sup>1</sup> Dong Wang,<sup>1</sup> Bjarne Bogen,<sup>1,5</sup> Geir E. Tjønnfjord,<sup>4</sup> Kjetil Taskén<sup>2,3,6#</sup> and Ludvig A. Munthe<sup>1#</sup>

<sup>1</sup>Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo; <sup>2</sup>Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital; <sup>3</sup>Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo; <sup>4</sup>Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo; <sup>5</sup>KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo; and <sup>6</sup>Department of Infectious Diseases, Oslo University Hospital, Norway

\*APR, SSS and SB contributed equally to this work

#KT and LAM contributed equally to this work

Correspondence: kjetil.tasken@ncmm.uio.no or ludvig@medisin.uio.no  
doi:10.3324/haematol.2015.135590



### Supplementary Figure S1

Expression of the activation marker CD38 on CLL cells after CD40L stimulation and Syk inhibition. CLL cells from 10 patients were stimulated by irradiated CD40L<sup>+</sup> or untransfected L cells (unstimulated) in the presence of R406 using relevant *in vivo* concentrations or DMSO vehicle control. See also Figure 1C.

**(A)** Expression of the activation marker CD38 on CD19<sup>+</sup> CLL cells is shown in unstimulated condition, after CD40L stimulation with vehicle (DMSO) only, or after CD40L stimulation in the presence of R406.

**(B)** Mean fluorescent intensity of CD38-expression in CD19<sup>+</sup>CLL cells as shown in (A).

**Supplemental Table SI.** Patient information.

Patient identifier	Gender/age (years)*	Binet stage*	IgVH,% homology to germline <sup>1</sup>	CD38 (%) <sup>2</sup>	FISH	Observation time before treatment / Treatment (T) <sup>3</sup>
CLL105	F/56	A	VH3-23, 100 VH3-49, 94.8 (biallelic)	0	NA	96/Not T
CLL106	F/52	A	VH3-23, 95.2	1	NA	49/Not T
CLL107	M/38	A	VH3-30, 92.9	1	del(13q14)	84/Not T
CLL109	M/54	A	VH3, 93.8	1	NA	61/Not T
CLL110	M/49	A	VH6-01, 95.4	1	NA	89/Not T
CLL111	M/59	A	VH1-69, 91	2	NA	48/Not T
CLL114	M/55	A	VH3-23, 88.2	2	NA	78/Not T
CLL119	M/56	C	VH3-21, 98,7	NA	Normal karyotype	5/FCA
CLL121	M/64	C	VH4-39, 98,7	61	Normal karyotype	1/FCA
CLL125	M/44	A at diagnosis, progressed to C	VH1-18 98,1/ VH3-30 97,3 (biallelic)	0	Normal karyotype	10/FCA
CLL126	F/55	C	VH4-34, 95.4	1	del(13q14)	F-FC-FCR/A
CLL132	M/51	B	VH3-30, 100	94	del(13q14)	29/FC
CLL135	M/61	A at diagnosis, progressed to C	VH4-34, 100	50	Normal karyotype	36/FCR-A-BR
CLL136	F/66	A	VH3-30, 91,9	1	del(13q14)	52/Not T

\* :at diagnosis

NA: Not analyzed.

<sup>1</sup> IgVH family, percent homology to germline.

<sup>2</sup> Percentage of cells staining positive for CD38, above isotype control.

<sup>3</sup> Observation time, treatment-free months since diagnosis. Non-treated patients are marked with Not T. Treated patients have received regimens with the following drugs marked with abbreviations: F= Fludarabine; C = Cyclophosphamide; A=Alemtuzumab; R=Rituximab; BR=bendamustine. Cells were gathered before treatment except for CLL126 and CLL135. Patient CLL126 was initially treated with F, thereafter with FC, then FCR (aborted due to toxicity), and replaced by A monotherapy. Samples for CLL126 were gathered prior to FCR treatment. Patient CLL135 was initially treated with FCR, then A and finally BR. Samples were gathered between 2nd and 3rd treatment.